Target
SEL
1 abstract
Abstract
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.Org: City of Hope National Medical Center, Vanderbilt-Ingram Cancer Center, VCU Massey Cancer Center, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute,